Subscribe
shutterstock_1349461175_pavel_kapysh
Pavel Kapysh / Shutterstock.com
14 November 2019Big PharmaSaman Javed

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

Seattle Genetics has asked the American Arbitration Association (AAA) to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Americas
Seattle Genetics to acquire biotech company for $614m
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Americas
Seattle Genetics to acquire biotech company for $614m
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Americas
Seattle Genetics to acquire biotech company for $614m
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug